These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17245498)

  • 1. Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.
    Durosinmi MA; Ogbe PO; Salawu L; Oyekunle AA
    Singapore Med J; 2007 Jan; 48(1):e16-8. PubMed ID: 17245498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
    Mattiuzzi GN; Cortes JE; Talpaz M; Reuben J; Rios MB; Shan J; Kontoyiannis D; Giles FJ; Raad I; Verstovsek S; Ferrajoli A; Kantarjian HM
    Clin Cancer Res; 2003 Mar; 9(3):976-80. PubMed ID: 12631595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).
    Gulati AP; Saif MW
    Anticancer Res; 2012 Apr; 32(4):1375-7. PubMed ID: 22493373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.
    Pitini V; Arrigo C; Sauta MG; Altavilla G
    Leuk Res; 2009 Sep; 33(9):e143-4. PubMed ID: 19443031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of complete response after imatinib mesylate treatment of advanced GIST.
    Papaxoinis G; Nikolaou M; Lianos E; Gaglia A; Economopoulos T; Pectasides D
    Anticancer Res; 2006; 26(6C):4869-72. PubMed ID: 17214353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
    Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
    Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Imatinib and solid tumours].
    Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
    Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Gastrointestinal stromal tumour: our experience].
    Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
    Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
    Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
    Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment of huge peritoneal metastasis from duodenal gastrointestinal stromal tumor resistant for imatinib mesylate].
    Sakakura C; Kumano T; Mizuta Y; Yamaoka N; Sagara Y; Hagiwara A; Otsuji E
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):2144-6. PubMed ID: 18219926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors.
    Han H; Yu YY; Wang YH
    J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S80-3. PubMed ID: 19119132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.